Needham & Company Downgrades Gilead Sciences (GILD) to Hold
Get Alerts GILD Hot Sheet
Rating Summary:
24 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Needham & Company downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
Analyst Alan Carr commented, "Gilead reported 2Q16 financial results yesterday. Product sales of $7.65B were consistent w/ our $7.71B and consensus $7.77B expectations. WW Harvoni and Sovaldi sales were $2.56B and $1.36B respectively, compared to consensus $2.87B and $1.19B. Mgmt lowered 2016 revenue guidance by $500M to $29.5B-30.5B, citing challenges in HCV, including fewer pt starts and shorter tx duration, contributing to decline in revenue/ pt. We expect this trend to continue.
Although we expect Gilead to retain generally dominant share in HCV and regain momentum w/ launch of TAF/FTC/BIC in HIV, overall revenue growth is a concern. We are downgrading to HOLD (was BUY). Favorable view may be restored w/ more evidence of substantial growth potential derived from M&A or internal pipeline. Areas of opportunity include HBV, liver disease, and oncology."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $88.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
- Gilead Sciences (GILD) April weekly option implied volatility into quarter results
- Boston Scientific (BSX) PT Raised to $83 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, DowngradesRelated Entities
Needham & Company, Earnings, Alan CarrSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!